Physician profile
Andrew Simon
NPI 1215032453
$3,516.80
in general payments reported to CMS, 2019-2025
15 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $81.26 · 2021: $46.98 · 2022: $284 · 2023: $671 · 2024: $854 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,426.57 | 2019-2025 | Precision 1, Dailies Total1, Air Optix Color |
| Sun Pharmaceutical Industries INC. | $764.67 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $303.23 | 2022-2025 | Xiidra, Miebo, Infuse |
| Oyster Point Pharma, INC. | $244.73 | 2023-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $202.71 | 2022-2025 | Acuvue |
| Glaukos Corporation | $130.88 | 2024 | Photrexa |
| Coopervision INC. | $87.69 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $84.52 | 2019 | |
| Abb Con-Cise Optical Group LLC | $75.94 | 2020-2023 | Spectacle Lenses, Contact Lens |
| Novartis Pharmaceuticals Corporation | $58.30 | 2021-2022 | |
| Dompe US, INC. | $46.86 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.57 | 2019-2020 | |
| Rxsight INC | $23.73 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Menicon America INC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.